Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Narrative (Details)

v3.21.2
Revenue Recognition - Narrative (Details) - USD ($)
3 Months Ended 6 Months Ended 78 Months Ended
May 05, 2020
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Dec. 31, 2020
Disaggregation of Revenue [Line Items]              
Prior period performance obligation revenue recognized       $ 28,500,000 $ 200,000    
Overpayment reimbursement liability   $ 9,500,000   9,500,000   $ 9,500,000 $ 14,900,000
Revenue recognized       7,425,000      
Total revenues   442,408,000 $ 301,207,000 987,573,000 512,674,000    
Rayaldee              
Disaggregation of Revenue [Line Items]              
Revenue recognized   5,000,000.0 8,600,000 8,600,000 18,600,000    
Total revenues   16,122,000   31,767,000      
Transfer of intellectual property and other              
Disaggregation of Revenue [Line Items]              
Total revenues   9,548,000 20,880,000 13,816,000 30,433,000    
Products | Transfer of intellectual property and other              
Disaggregation of Revenue [Line Items]              
Total revenues $ 3,000,000            
Pfizer | Products              
Disaggregation of Revenue [Line Items]              
Revenue recognized           $ 0  
Pfizer | Products | Transfer of intellectual property and other              
Disaggregation of Revenue [Line Items]              
Total revenues   2,800,000 13,900,000 5,600,000 22,700,000    
Nicoya | Products | Transfer of intellectual property and other              
Disaggregation of Revenue [Line Items]              
Total revenues   $ 5,000,000.0   $ 5,000,000.0      
BioReference | Products | Transfer of intellectual property and other              
Disaggregation of Revenue [Line Items]              
Total revenues     $ 6,200,000   $ 6,200,000